Direct Biologics
exit covid phase trial results phase exit covid mortality time | Direct Biologics
Company
Deck Type
Deck date
October 2022
Slide
21 of 36
Related slides by other companies
Ocuphire Pharma
Results
March 2021
secondary mean pupil diameter over time | Ocuphire Pharma
GH Research
Investor Presentation
March 2023
phase clinical pharmacology trial in healthy volunteers completed | GH Research
Recursion Pharmaceuticals
Investor Day
January 2023
clinical finalize design of a phase enriched trial initiate phase trial in select tumor types in early identify suitable partners for genetic testing capabilities evaluate in combination with targeted and or immune modulating agents next steps | Recursion Pharmaceuticals
Recursion Pharmaceuticals
Investor Day
January 2023
clinical phase sad mad trial initiated in trial design randomized double blind trial population healthy subjects sad mad primary objectives assess the safety tolerability of sad and mad of evaluate the profile of after single and multiple doses trial update enrollment is progressing in several sad cohorts and at least one cohort has been extremely safe and well tolerated complete safety and data expected study underway | Recursion Pharmaceuticals
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io